Clinical Trials Logo

Clinical Trial Summary

This is a prospective, multicenter, randomized phase III trial among women with endometrioid adenocarcinoma with high-intermediate and intermediate risk features to investigate the role of integrated genomic-pathologic classification to determine if participants should receive no adjuvant therapy, vaginal brachytherapy, external beam radiotherapy or chemo-radiation therapy based on molecular features as compared to standard radiation therapy.

Clinical Trial Description

Adjuvant therapy for women with endometrial cancer has increasingly been tailored to prognostic factors to prevent overtreatment and select those women for adjuvant treatment who will have a clinically relevant reduction of the risk of relapse by the adjuvant treatment. Risk profiles have traditionally been based on clinicopathological factors such as age, stage, grade, LVSI and depth of invasion. Newer, both molecular-genetic (the cancer genome atlas subgroups) have become available which are strongly related to outcomes and risk of cancer spread. Based on the recent 2022 NCCN guideline and Portec-4a study, this randomized trial using integrated genomic-pathologic classification to assign adjuvant treatment for women with stage I-II high-intermediate and intermediate risk endometrioid adencarcinoma. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05179447
Study type Interventional
Source Women's Hospital School Of Medicine Zhejiang University
Contact Xinyu Wang, MD
Phone +86-571-87061501
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date January 1, 2022
Completion date January 1, 2026

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04046185 - Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer Early Phase 1
Recruiting NCT03469674 - PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer Phase 3
Recruiting NCT04792749 - Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer Phase 3
Recruiting NCT04972682 - [SENTRY] Sentinel Lymph Node Biopsy Predictive Value in Endometrial Cancer of Low and Intermediate Risk N/A
Recruiting NCT04073706 - Sentinel Node Biopsy in Endometrial Cancer Phase 3
Recruiting NCT04291612 - Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
Recruiting NCT04839614 - Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia N/A
Recruiting NCT03580421 - Cost-utility of Ambulatory Surgery in the Management of Endometrial Cancer(AMBU-ENDO) N/A